Amgen
↗Thousand Oaks, California, United States
Amgen is one of the world's leading independent biotechnology companies, founded in 1980 and headquartered in Thousand Oaks, California. The company discovers, develops, manufactures, and delivers innovative human therapeutics for serious illnesses including cancer, cardiovascular disease, inflammation, osteoporosis, and rare diseases. Amgen operates a robust, diverse pipeline leveraging state-of-the-art science and molecular engineering focused on transformative medicines with significant clinical effects. The company maintains a strong global presence with manufacturing and R&D facilities across North America, Europe, and Asia, and generated $33.4 billion in revenue in 2024.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology, Inflammation, Metabolic Disease, Cardiovascular, Rare Disease, Immunology
SIZE & FINANCIALS
Employees:10000+
Revenue:$33.4B
Founded:1980
Ownership:public
Status:operating
FUNDING
Stage:N/A
STOCK
Exchange:NASDAQ
Ticker:AMGN
Market Cap:$177.1B
PIPELINE
Stage:Discovery through Commercial
Lead Drug Stage:Phase 3 (MariTide for obesity, Rocatinlimab for atopic dermatitis)
Modalities:Monoclonal antibodies, Peptide-antibody conjugates, Small molecules, Biologics, Biosimilars, Cell therapy
Active Trials:85
Trial Phases:Phase 1: 41 | Phase 2: 32 | Phase 3: 12
FDA Approvals:50
CORPORATE STRUCTURE
Subsidiaries:Horizon Therapeutics (acquired 2023), Rodeo Therapeutics (acquired 2021)
Key Partnerships:AstraZeneca: Co-development and commercialization of Tezspire (tezepelumab), Veeva Systems: Clinical trial process enhancement, Kyowa Kirin: Co-development of rocatinlimab (atopic dermatitis), Sanofi: Collaboration on Ordesekimab (via Provention Bio, Sanofi Company), Xencor: Collaboration on Xaluritamig (AMG 509), Cognizant Technology Solutions & UiPath: Automation and operational efficiency
COMPETITION
Position:Leader
Competitors:Eli Lilly, AbbVie, Pfizer, Roche/Genentech, Novartis, Johnson & Johnson, Merck, Bristol Myers Squibb
LEADERSHIP
Key Executives:
Robert A. Bradway - Chairman and Chief Executive Officer
Peter H. Griffith - Chief Financial Officer & Executive Vice President, Finance
David M. Reese - Executive Vice President & Chief Technology Officer
Sean E. Harper - Executive Vice President of Research & Development
Scott Skellenger - Senior Vice President & Chief Information Officer
Scientific Founders:William K. Bowes Jr., George Rathmann
Board Members:Wanda M. Austin, Robert A. Bradway, Michael V. Drake, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Charles M. Holley Jr., S. Omar Ishrak, Tyler Jacks, Mary E. Klotman, Ellen J. Kullman, Amy E. Miles
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Amgen and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Amgen. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.